Register / Log In

Health app downloads stagnate among cell phone users during past year, survey finds


About 11% of U.S. adult cell phone users downloaded an application (or app) that “helped them track or manage their health” in August 2011, according to a survey by Pew Research Centers’ Internet & American Life Project.

For more than a year, Pew has tracked the adoption of health apps by U.S. adults. In September 2010, Pew found that about 9% of all U.S. adults had downloaded an app to help manage their health.

But due to a change in the way the 2 surveys were conducted, Pew characterized the slight increase as “statistically insignificant,” meaning app adoption has been largely stagnant during the past 12 months. In August 2011, the question was asked of adults who have downloaded an app to a cell phone or tablet computer, rather than all cell phone users. “More than one-quarter of this population (29%) report downloading a health app,” Pew wrote. “Looking just at adults who download apps to a cell phone, this translates to 11% of all adult cell phone users having downloaded an app that helps them manage their health.”

Overall, the survey showed the share of adult cell phone owners who have downloaded any type of app to their phone increased during the past 2 years – from 22% in September 2009 to 38% in August 2011. The share of U.S. adults who purchased a phone already equipped with apps also increased during the past year, from 38% in May 2010 to 43% in August 2011.

Merck has announced in a prepared statement that its contraceptive implant (Nexplanon) is now available in the United States.

The California Pharmacists Association (CPhA) and PrescribeWellness, a healthcare digital communication solutions provider, are partnering on the “One Million More” flu shot campaign to increase the yearly influenza vaccination rate.

Consultation with non-specialist pharmacists did not improve rates of hospitalization or death for patients with left ventricular systolic dysfunction (heart failure), according to the results of a large-scale, long-term prospective randomized trial conducted by the National Health Service and reported at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla.

In this section we showcase products and product news that ran up against space limitations or fell outside the parameters of recently featured categories in the print edition.

Rivaroxaban (Xarelto, Janssen Pharmaceuticals), an oral anticoagulant that directly inhibits factor Xa, reduced the risk of death, myocardial infarction, and stroke in patients with acute coronary syndrome, according to a report presented at the American Heart Association's Scientific Sessions 2011, Orlando, Fla.